TScan Therapeutics (NASDAQ: TCRX) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 17.86 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $1.051 million which missed the analyst consensus estimate of $1.667 million by 36.94 percent. This is a 65.83 percent decrease over sales of $3.076 million the same period last year.